Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
November 30, 2023 – Pharmaceutical – Biocon, Biocon Biologics, biosimilars
30 November 2023 — Bengaluru, India — Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed.
Following the acquisition of substantially all of the global biosimilar business of Viatris in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, the full transition of Viatris’ biosimilars operations to BBL in Europe represents another significant milestone as a world-leading biosimilars company.
In Europe, BBL’s portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab and Etanercept. At a global level, BBL has a robust pipeline of 20 assets for diabetology, oncology, immunology, ophthalmology and bone health. Serving over 5.7 million patients annually, the company is committed to providing access to high-quality therapies and solutions to patients, healthcare systems and governments across the globe.
Shreehas Tambe, CEO and managing director, Biocon Biologics Ltd, said: “The integration of the Viatris’ biosimilar business in Europe ahead of schedule is another important milestone for Biocon Biologics in our journey as a global biosimilars leader. We are pleased to expand access to life-saving treatments for patients across Europe. Our unique, fully integrated capabilities and robust pipeline of 20 products will allows us to better address patient needs and be a reliable partner to health organisations.”
Jozef Belcik, head of Commercial Europe and JANZ, Biocon Biologics Ltd, said: “We are extremely pleased to have reached this historic moment and we are proud to lead the way in the advancement of biosimilars. As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution and commercialisation of biosimilars in Europe and in the world.”
After the acquisition from Viatris, BBL and its partners will commercialise biosimilar products in the following countries: Albania, Austria, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland and the UK.
About Biocon Biologics Limited
Biocon Biologics Ltd, a subsidiary of Biocon Ltd, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has acquired substantially all of the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. BBL has commercialised eight biosimilars in key emerging markets and advanced markets like US, Europe, Australia, Canada and Japan. The company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com.
